129 related articles for article (PubMed ID: 15636484)
1. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls.
Sterling TR
Int J Tuberc Lung Dis; 2004 Dec; 8(12):1396-400. PubMed ID: 15636484
[TBL] [Abstract][Full Text] [Related]
2. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
[TBL] [Abstract][Full Text] [Related]
3. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.
Yoon YS; Lee HJ; Yoon HI; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Int J Tuberc Lung Dis; 2005 Nov; 9(11):1215-9. PubMed ID: 16333927
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.
Ginsburg AS; Hooper N; Parrish N; Dooley KE; Dorman SE; Booth J; Diener-West M; Merz WG; Bishai WR; Sterling TR
Clin Infect Dis; 2003 Dec; 37(11):1448-52. PubMed ID: 14614666
[TBL] [Abstract][Full Text] [Related]
5. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.
Low DE
Clin Infect Dis; 2009 May; 48(10):1361-3. PubMed ID: 19348596
[No Abstract] [Full Text] [Related]
7. Fluoroquinolone use with no increase in culture-negative tuberculosis.
Matsushima M; Yamamoto S; Iwata K; Gremillion DG
Arch Intern Med; 2008 Sep; 168(16):1824-5; author reply 1825. PubMed ID: 18779473
[No Abstract] [Full Text] [Related]
8. [Investigation of Mycobacterium tuberculosis sensitivity to fluoroquinolone, by revealing gyrA gene mutations].
Nosova EIu; Galkina KIu; Markova OV; Griadunov DA; Skotnikova OI
Probl Tuberk Bolezn Legk; 2007; (10):57-60. PubMed ID: 18051841
[TBL] [Abstract][Full Text] [Related]
9. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey.
Umubyeyi AN; Rigouts L; Shamputa IC; Fissette K; Elkrim Y; de Rijk PW; Struelens MJ; Portaels F
J Antimicrob Chemother; 2007 May; 59(5):1031-3. PubMed ID: 17329272
[TBL] [Abstract][Full Text] [Related]
10. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.
Gaba PD; Haley C; Griffin MR; Mitchel E; Warkentin J; Holt E; Baggett P; Sterling TR
Arch Intern Med; 2007 Nov; 167(21):2317-22. PubMed ID: 18039990
[TBL] [Abstract][Full Text] [Related]
11. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
Grossman RF; Hsueh PR; Gillespie SH; Blasi F
Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
[TBL] [Abstract][Full Text] [Related]
12. Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India.
Agrawal D; Udwadia ZF; Rodriguez C; Mehta A
Int J Tuberc Lung Dis; 2009 Jan; 13(1):79-83. PubMed ID: 19105883
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada.
Bozeman L; Burman W; Metchock B; Welch L; Weiner M;
Clin Infect Dis; 2005 Feb; 40(3):386-91. PubMed ID: 15668861
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary tuberculosis presenting as community-acquired pneumonia.
Asnis DS; Cherian S; Sun T; Shrestha S; Santucci T
Clin Infect Dis; 2002 Dec; 35(12):1574-5. PubMed ID: 12471584
[No Abstract] [Full Text] [Related]
15. Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance.
Cox H; Kebede Y; Allamuratova S; Ismailov G; Davletmuratova Z; Byrnes G; Stone C; Niemann S; Rüsch-Gerdes S; Blok L; Doshetov D
PLoS Med; 2006 Oct; 3(10):e384. PubMed ID: 17020405
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
[TBL] [Abstract][Full Text] [Related]
17. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
Ferrara AM
Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
[TBL] [Abstract][Full Text] [Related]
18. [Impact of fluoroquinolone use on multidrug-resistant bacteria emergence].
Nseir S; Ader F; Marquette CH; Durocher A
Pathol Biol (Paris); 2005; 53(8-9):470-5. PubMed ID: 16176863
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis.
Chen TC; Lu PL; Lin CY; Lin WR; Chen YH
Int J Infect Dis; 2011 Mar; 15(3):e211-6. PubMed ID: 21195001
[TBL] [Abstract][Full Text] [Related]
20. The early bactericidal activity of anti-tuberculosis drugs: a literature review.
Donald PR; Diacon AH
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S75-83. PubMed ID: 18762155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
